About TRANSCENTA-B Company

We are a clinical-stage biopharmaceutical company with comprehensive capabilities to discover, research, develop, and manufacture differentiated antibody drugs for treatment areas with huge gaps in medical demand (including tumors, kidney disease, and bone diseases). Our management team and main business (including clinical development, regulatory access and business development) are located in the US and China, while our discovery, R&D, process development and production teams are all located in China. Since our inception, we have been committed to a global strategy and vision. We work hard to develop molecules with global intellectual property rights and design and conduct multi-regional clinical trials to meet national and international regulatory requirements, which will help create a global commercial channel for our products. We have developed a uniquely functional antibody discovery platform, the Immune Tolerance Breakthrough (IMTB) technology platform, which enables us to build a diversified and risk-balanced antibody product pipeline with best-in-class or pioneering potential. With the help of the IMTB technology platform, we have internally discovered and developed nine out of ten candidate antibodies, enabling us to generate antibodies that are difficult to discover through traditional platforms, helping us select candidate molecules with better pharmacogenicity and high commercial potential. TST001 (our focus project, with best-in-class potential) is a high-affinity humanized antibody that specifically targets Claudin18.2. This target is overexpressed in a variety of cancers, including gastric or gastroesophageal junction cancer, pancreatic cancer, biliary tract cancer, and other types of solid tumors. TST001 is now preparing for critical global trials, pending regulatory review by regulators of favorable data on its efficacy, safety and tolerability. All of the molecules we are currently developing have a comprehensive set of translational research strategies to realize their full clinical and commercial potential. By enhancing the role of translational science, we can better understand disease biology to design and conduct our clinical studies and support us in identifying the right patient groups to improve the likelihood of successful trials. We have established a fully integrated CMC functional department with full capabilities from developability assessment, cell line development, process and analytical development to DS and DPGMP production, and have established a comprehensive QA, QC and quality management system to meet production needs and ensure stable high-quality products. Since 2018, our T-BLOC facility has been producing cell banks, DS, and DP for internal and external toxicological studies, phase I, phase II, and phase III clinical trials. Our proprietary integrated continuous flow bioprocess (“ICB”) platform has demonstrated industry-leading volumetric productivity, enabling us to maximize output while reducing production costs. Through our integrated continuous flow bioprocessing platform, we have achieved the industry's best productivity of more than 6g/L per day, which is more than 10 times higher than traditional flow processing techniques. With our industry-leading CMC capabilities, we also provide quality CDMO services and generate cash flow to our growing customer base. Cooperation and collaboration are an important part of our strategy. Our differentiated products and cutting-edge technology platforms provide leverage and flexibility in how we structure partnerships. We have made significant progress in discussions with a range of potential partners who can provide a broad range of commercial infrastructure to bring our projects to various markets. Our core management team members have an average of over 15 years of experience and a strong track record, as well as balanced expertise in research, clinical development, manufacturing, planning and financing. Our shareholders include global and Chinese biotechnology-focused specialist funds and biopharmaceutical platforms experienced in supporting and developing biopharmaceutical companies. As a result, we will benefit from their industry expertise and resources. Our experienced team, fully integrated capabilities, and a differentiated yet risk-balanced product line are the cornerstones of our mission to discover, develop and deliver affordable, innovative medicines to help patients around the world.